12:00 AM
Jul 21, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AMT-021: Interim Phase I data

Interim data from an open-label, dose-ranging, Spanish Phase I trial in 8 patients with severe acute intermittent porphyria showed that a single IV injection of up to 2x10 13 genetic components/kg AMT-021 was well tolerated with no treatment-related serious adverse events and no changes in blood...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >